Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03828747
Recruitment Status : Active, not recruiting
First Posted : February 4, 2019
Last Update Posted : March 15, 2022
Information provided by (Responsible Party):
Genentech, Inc.

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 20, 2021
Estimated Study Completion Date : August 23, 2023
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 July 15, 2022
August 10, 2022 Submission with QC Comments